DNLI – denali therapeutics inc. (US:NASDAQ)
Stock Stats
News
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Form 10-K Denali Therapeutics Inc. For: Dec 31
Form S-8 Denali Therapeutics Inc.
Form 8-K Denali Therapeutics Inc. For: Feb 26
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.